Reaction

Prostatitis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,996 reports · 67 co-occurring drugs

As of the last recalculation, Prostatitis appears in 2,996 FAERS reports alongside 67 co-occurring drug terms. The strongest observed disproportionality signal is FINASTERIDE (PRR 24.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Finasteride	200	24.6	24.7
Tamsulosin Hydrochloride	37	12.7	12.8
Ciprofloxacin	154	12.2	12.3
Ciprofloxacin Hydrochloride And Hydrocortisone	36	12.2	12.2
Ciprofolxacin	120	12.1	12.1
Ciprofloxacin Tablets	120	12.1	12.1
Ciprofloxacin Hydrochloride	159	11.9	12.0
Trimethoprim	17	10.1	10.1
Salmeterol Xinafoate	12	9.7	9.7
Canagliflozin	38	8.9	8.9
Nitrofurantoin	20	8.5	8.5
Nitrofurantoin (Monohydrate/Macrocrystals)	20	8.4	8.4
Bicalutamide	18	8.2	8.3
Terazosin Hydrochloride	10	7.8	7.8
Valganciclovir	21	7.8	7.8
Valganciclovir Hydrochloride	21	7.8	7.8
Cimetidine	10	7.2	7.2
Baricitinib	10	7.2	7.2
Eplerenone	13	7.1	7.1
Relugolix	23	6.8	6.8
Empagliflozin	62	6.5	6.5
Valganciclovir Hydrochloride Powder,	11	6.3	6.3
Testosterone Cypionate	8	6.2	6.2
Infliximab-Dyyb	26	6.2	6.2
Cabotegravir	7	6.0	6.0
Doxazosin Mesylate	31	6.0	6.0
Dutasteride	7	6.0	6.0
Basiliximab	10	5.9	5.9
Atropine	7	5.9	5.9
Amlodipine Besylate And Valsartan	9	5.7	5.7
Atomoxetine Hydrochloride	19	5.6	5.6
Dolutegravir Sodium	7	5.4	5.4
Amoxicillin And Clavulanate Potassium	21	5.4	5.4
Doxazosin	19	4.7	4.7
Dofetilide	7	4.6	4.6
Glyburide	16	4.6	4.6
Tacrolimus	98	4.5	4.5
Tacrolimus Ointment 0.1%	76	4.3	4.3
Tacrolimus Extended-Release Capsules	76	4.3	4.3
Dapagliflozin	19	4.2	4.2
Ceftriaxone Sodium	23	4.2	4.2
Insulin Glulisine	6	4.1	4.1
Abiraterone	8	4.1	4.1
Bendamustine Hcl	9	4.0	4.0
Tadalafil	57	4.0	4.0
Granisetron Hydrochloride	6	4.0	4.0
Granisetron	6	4.0	4.0
Fesoterodine Fumarate	6	3.9	3.9
Tofacitinib Citrate	7	3.7	3.7
Ibrutinib	41	3.6	3.6
Abiraterone Acetate	17	2.9	2.9
Venetoclax	25	2.8	2.8
Ribavirin	25	2.7	2.7
Paricalcitol	5	2.5	2.5
Apalutamide	4	2.4	2.4
Azacitidine	10	2.3	2.3
Acalabrutinib	4	2.3	2.3
Atezolizumab	12	2.2	2.2
Suvorexant	4	2.1	2.1
Encorafenib	3	2.1	2.1
Leuprolide Acetate	23	2.1	2.1
Glecaprevir And Pibrentasvir	3	1.9	1.9
Enzalutamide	16	1.9	1.9
Emtricitabine And Tenofovir Alafenamide	3	1.8	1.8
Ixekizumab	9	1.7	1.7
Evolocumab	18	0.8	0.8
Salicylic Acid	4	0.5	0.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.